Efficacy and safety analysis of combined therapy with recombinant human endostatin and programmed death-1 inhibitor for advanced non-small cell lung cancer
Hou Chunli
Xu Jiarui
He Qiang
Zhu Tienian
Wu Honghai
Chen Hong
Xue Qian
Abstract：Objective To investigate the clinical efficacy and safety of continuous intravenous infusion of recombinant human endostatin in combination with programmed death-1(PD-1)inhibitor for advanced non-small cell lung cancer(NSCLC).Methods Totally 90 patients with advanced NSCLC admitted to 980th Hospital of the Joint Service Support Force of the Chinese People's Liberation Army were retrospectively selected from January 2020 to January 2022.They were divided into groups A,B and C,30 cases in each group,based on distinct treatment protocols.Group A received PD-1 inhibitor+recombinant human endostatin injection,and platinum-containing two-drug treatment.Group B received PD-1 inhibitor and platinum-containing two-drug.Group C received recombinant human endostatin injection and platinum-containing two-drug.The primary endpoints included the objective remission rate(ORR)and progression-free survival(PFS),with secondary endpoints being the disease control rate(DCR)and safety.Results Statistically significant differences were observed in ORR and DCR among the three groups(P=0.039,0.018),with the highest ORR and DCR[50.0％(15/30),83.3％(25/30)]in group A.The median PFS was 7.4,5.6,and 5.7 months in groups A,B,and C,respectively,and there was statistically significant difference among the three groups(P＜0.001).Multivariate Cox regression model analysis revealed that gender,epidermal growth factor receptor mutation,and the number of metastatic organs were risk factors affecting the PFS of advanced NSCLC patients(all P＜0.05).In group A,there were 55 cases of adverse reactions,including 4 cases classified as serious adverse reactions(grades 3-4).Group B had 54 cases of adverse reactions,with 4 cases classified as serious adverse reactions(grades 3-4).Group C experienced 51 cases of adverse reactions,including 2 cases classified as serious adverse reactions(grades 3-4).Conclusion The combination of recombinant human endostatin and PD-1 inhibitor exhibited favorable clinical efficacy in treating advanced NSCLC,with relatively manageable adverse reactions.
Keywords：Non-small cell lung cancerRecombinant human endostatinProgrammed death-1 inhibitor
Publication Date：2024-03-08
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：6( 366-371 )